|
Symposium
[Free Online Symposium] Promising Biotech Startups: Their Science and Stories
Speakers:
Darren Cooke, Life Sciences Entrepreneurship Center, UC Berkeley; Sam Lai, Inhalon; Sigi Neerken, InnoSIGN; Scott Shively, Bexion; Angela Lai, Betteromics; Robert Li, LTZ Therapeutics; Matthew O'Connor, Cyclarity; Cindy McReynolds, EicOsis
Organizers:
Toby Freedman PhD, Synapsis Search Recruiting; Shichang Miao PhD, Amgen; Donald McCarthy PhD, Samsara BioCapital; Elina Lavit, OncoNano Medicine Inc.
Date:
2023-02-06
Time:
8:30-13:30 Pacific Time
Registration fee:
0
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2023-02-03
(it will close sooner if the seating cap is reached)
About the Topic
Note: This is an online meeting, The Zoom link will be sent to the registrants 1+ days before the event. About the Speakers
PST
|
EST
|
Topic
|
Presenter
|
8:30-8:40 am
|
11:30-11:40 am
|
Welcome Remarks
|
Shichang Miao
|
8:40-9:15 am
|
11:40-12:15 pm
|
InnoSIGN: Revolutionize precision medicine through OncoSIGNal pathway activity profiling
|
Sigi Neerken, PhD, Co-founder and Chief Business Officer, InnoSIGN
|
9:15-9:50 am
|
12:15-12:50 pm
|
The role of angel investors and startup accelerators in the life sciences startup and fundraising ecosystem
|
Darren Cooke, JD. Executive Director, Life Sciences Entrepreneurship Center, UC Berkeley
|
9:50-10:25 am
|
12:50-1:25 pm
|
Bexion Pharmaceuticals: Leveraging biologic immunotherapy to treat solid tumor cancers
|
Scott Shively, CEO & President, BexionPharmaceuticals, Inc.
|
10:25-10:35 am
|
1:25-1:35 pm
|
Break
|
-
|
10:35-11:10 am
|
1:35-2:10 pm
|
Betteromics: A data operating system for the modern life science enterprise
|
Angela Lai, CEO, Betteromics Inc.
|
11:10-11:45 am
|
2:10-2:45 pm
|
LTZ Therapeutics: Lift to Zenith with novel immunotherapies
|
Robert Li, PhD, Co-founder & CEO, LTZ Therapeutics
|
11:45-12:20 pm
|
2:45-3:20 pm
|
Cyclarity Therapeutics: Targeting oxidized cholesterol to reverse atherosclerosis: a new drug and a new paradigm
|
Matthew O’Connor, Ph.D., Co-CEO, CyclarityTherapeutics
|
12:20-12:55 pm
|
3:20-3:55 pm
|
EicOsis: From horses to humans: Identification of a novel drug target, the soluble epoxide hydrolase, for the treatment of pain and chronic inflammation
|
Cindy McReynolds, PhD, CEO, EicOsis
|
12:55-1:30 pm
|
3:55-4:30 pm
|
TBD
|
Sam Lai, Founder / CSO, Inhalon
|
1:30-2:00 pm
|
4:30-5:00 pm
|
Panel Discussion
|
All Speakers
|
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Online Workshop] Career Transition for Research Scientists
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|